August 13th 2025
Sandoz will oversee commercialization of the product across the European Union (excluding Germany), Switzerland, Norway, Australia, Hong Kong, Vietnam, and Malaysia under the terms of the agreement.
4DMT accelerating 4D-150 4FRONT phase 3 program, laying off 25% of staff
July 7th 2025The company notes that the workforce reduction is expected to provide annual cash compensation cost savings of approximately $15 million and offsets additional expenses expected based on the accelerated timelines for the 4FRONT clinical trials.
Read More
Valorum Biologics to commercialize Formycon’s Eylea Biosimilar FYB203 in US and Canada
June 26th 2025FYB203 has been approved by the US FDA and UK Medicines and Healthcare products Regulatory Agency for the treatment of neovascular age-related macular degeneration (nAMD), diabetic macular edema, macular edema following retinal vein occlusion, and visual impairment due to myopic choroidal neovascularization.
Read More
Study shows genetic link between instant coffee consumption and increased risk of dry AMD
June 20th 2025To conduct the study, the investigators obtained data on coffee consumption from genome‐wide association studies (GWAS) and the latest AMD‐related GWAS summary data from the Finngen consortium R11.
Read More
NIH scientists develop new surgical technique for grafting tissue in the retina
May 28th 2025The new surgical technique incorporates a new surgical clamp that maintains eye pressure during the insertion of 2 tissue patches in immediate succession while minimizing damage to the surrounding tissue.
Read More